Related Experiment Video
Updated: Aug 4, 2026
07:25
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Neoadjuvant hormonal therapy prior to radical prostatectomy: the European experience
1Department of Urology, University Medical Center, Nijmegen, The Netherlands. F.debruyne@uro@azn.nl
Molecular Urology
|November 4, 2000
Summary
Neoadjuvant hormonal therapy (NHT) for prostate cancer showed a trend toward reduced PSA progression but did not reach statistical significance. Further trials are needed to determine its true benefit in specific patient groups.
Area of Science:
- Oncology
- Urology
Background:
- Neoadjuvant hormonal therapy (NHT) has been used for prostate cancer for over a decade.
- Clinical trial results are emerging, but the treatment's value remains unclear.
Purpose of the Study:
- To review European randomized trial results to clarify the role of NHT in prostate cancer treatment.
- To understand the impact of NHT on disease progression and outcomes.
Main Methods:
- A study involving 402 prostate cancer patients (220 T2, 182 T3).
- 192 patients received 3-month NHT (LHRH analog + flutamide); 210 underwent radical prostatectomy (RP) only.
- Randomized assignment to NHT or RP groups.
Main Results:
- Pathologic downstaging occurred in 15% of NHT patients vs. 7% in RP (P < 0.01).
- Disease progression (rising PSA) was observed in 26% of NHT patients and 33% of RP patients.
- Local disease progression showed a trend favoring NHT (10% vs. 16%, P = 0.07), but not statistically significant.
Conclusions:
- A trend favoring NHT for PSA and local disease progression was noted but lacked statistical significance.
- The lack of significance may indicate no true benefit or insufficient statistical power.
- Further research is needed to identify patient subsets who may benefit from NHT.
